Rheumatology
Early RA synovium splits into two expression/histology groups
Open access · cc by · source: Europe PMC
Targeted knee synovial biopsies from early RA patients clustered into two major gene-expression groups with different histological scores, showing molecular heterogeneity even early in disease.
Study at a glance
- Design
- Other — Arthroscopic targeted synovial biopsy histopathology + expression clustering
- N
- N=16 · 12 early RA (<1 year) and 4 long-standing RA; 18 samples from 16 cases
- Population
- Adults with early or long-standing rheumatoid arthritis undergoing targeted synovial biopsy
- Outcome
- Histopathology and gene-expression subgroups of synovitis
Structured fields used in claim comparison tables when every cited study has a complete layer.
Key findings
Eighteen samples from 16 cases formed two major expression groups. Group II vs I showed 180 genes up and 235 down (Q<5%), with significant histological score differences between groups — evidence that early RA synovitis is not one molecular state.
Methodology
Authors obtained arthroscopic targeted synovial biopsies from 12 early RA patients (<1 year) and 4 long-standing RA patients, then compared histopathology with gene-expression clustering.
Limitations
Two clusters in a small biopsy series do not define treatment arms. Arthroscopic knee samples may not represent every joint. Expression differences are associative with histology, not proven drug targets by themselves.
How this study connects
Role on claims
Each row is a claim on a concept or method page where this paper supports, challenges, or qualifies the statement. Roles are hand-checked — not a model guess.
GSK2982772 (RIPK1) looked similar to placebo on RA activity at tested exposures.
In a 52-patient placebo-controlled experimental-medicine study on stable csDMARDs, safety was primary and DAS28-CRP/ACR outcomes were similar between GSK2982772 and placebo — authors conclude no meaningful clinical improvement at evaluated exposures.
Scope note — tissue heterogeneity biology, not a drug RCT
Limits the claim's scope: a different population, assay, or outcome.
Early RA synovium already shows two expression/histology clusters.
Targeted arthroscopic biopsies from early RA clustered into two major gene-expression groups with different histological scores — molecular heterogeneity early in disease, not a treatment-assignment tool by itself.
Evidence for the claim as stated.
A null RIPK1 activity signal, an MTD for seliciclib, and early synovium clusters are different evidence types. Pathway interest does not transfer efficacy across programmes.
Evidence for the claim as stated.
Open questions
Tensions this paper is part of
From concept pages' “where studies disagree.” Disagreement means the same question; scope means different assays, populations, or outcomes.
A null RIPK1 activity signal, an MTD for seliciclib, and early synovium clusters are different evidence types. Pathway interest does not transfer efficacy across programmes.
Related papers in this topic
Same topic cluster — not a recommendation engine.